cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.31113086.v1
title: The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity

description: Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (<i>α</i>-helix = 17%) is structurally denatured compared with native HSA (<i>α</i>-helix = 68%), leading to rapid clearance (&lt;1 h) from the circulation and that drug loading is driven by pharmaceutical HSA’s amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (<i>ζ</i> = −13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (&lt;0.1  mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (<i>ζ</i> = −27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (&lt;0.01  mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, <i>p</i> &lt; 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles. Created with Biorender.com.
DOI: 10.6084/m9.figshare.31113087
title: Social networks and exchanges of social support during stroke caregiving

description: The purpose of this study was to explore how caregivers of persons living with stroke (PLWS) navigate their social relationships and engage in exchanges of social support during caregiving. Ethnographic methods consisting of semi-structured interviews, a diary, and a network mapping activity were used. Interview data were analyzed using reflexive thematic analysis. Eight caregivers of PLWS participated in the study. Two main themes were generated. Social network members supported each other through information sharing. Caregivers supported others by sharing information about the PLWS and by acting as liaison between medical staff and family members. Some participants had to navigate conflict and strain within certain relationships during information sharing. Social network members were valuable sources of informational support for participants, which helped compensate for a lack of health care system support. The provision of social support helped lessen the load of caregiving by providing caregivers with space to focus on the PLWS, emotional support, and companionship and time away from caregiving responsibilities. The study identified beneficial forms of support for caregivers of PLWS. The findings have implications for caregiver education and support programs. Caring for a person living with stroke (PLWS) can affect how a caregiver interacts with the people in their social networkDifferent forms of social support from social network members can help lessen the load of caregiving through information sharing, practical assistance, empathy, and companionshipRehabilitation professionals working with caregivers of PLWS should inquire about caregivers’ social networks and availability of social support to help identify caregivers at risk of low support Caring for a person living with stroke (PLWS) can affect how a caregiver interacts with the people in their social network Different forms of social support from social network members can help lessen the load of caregiving through information sharing, practical assistance, empathy, and companionship Rehabilitation professionals working with caregivers of PLWS should inquire about caregivers’ social networks and availability of social support to help identify caregivers at risk of low support
DOI: 10.6084/m9.figshare.31113087.v1
title: Social networks and exchanges of social support during stroke caregiving

description: The purpose of this study was to explore how caregivers of persons living with stroke (PLWS) navigate their social relationships and engage in exchanges of social support during caregiving. Ethnographic methods consisting of semi-structured interviews, a diary, and a network mapping activity were used. Interview data were analyzed using reflexive thematic analysis. Eight caregivers of PLWS participated in the study. Two main themes were generated. Social network members supported each other through information sharing. Caregivers supported others by sharing information about the PLWS and by acting as liaison between medical staff and family members. Some participants had to navigate conflict and strain within certain relationships during information sharing. Social network members were valuable sources of informational support for participants, which helped compensate for a lack of health care system support. The provision of social support helped lessen the load of caregiving by providing caregivers with space to focus on the PLWS, emotional support, and companionship and time away from caregiving responsibilities. The study identified beneficial forms of support for caregivers of PLWS. The findings have implications for caregiver education and support programs. Caring for a person living with stroke (PLWS) can affect how a caregiver interacts with the people in their social networkDifferent forms of social support from social network members can help lessen the load of caregiving through information sharing, practical assistance, empathy, and companionshipRehabilitation professionals working with caregivers of PLWS should inquire about caregivers’ social networks and availability of social support to help identify caregivers at risk of low support Caring for a person living with stroke (PLWS) can affect how a caregiver interacts with the people in their social network Different forms of social support from social network members can help lessen the load of caregiving through information sharing, practical assistance, empathy, and companionship Rehabilitation professionals working with caregivers of PLWS should inquire about caregivers’ social networks and availability of social support to help identify caregivers at risk of low support
DOI: 10.6084/m9.figshare.30219914.v1
title: Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

description: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a systematic review with meta-analysis of studies involving patients with RA-ILD who were treated with RTX. Two investigators independently conducted the research. Twenty studies met the criteria for data extraction for the systematic review with a good quality assessment according to an 18-criteria checklist using a modified Delphi method. The total number of patients was 14,523, including 1,619 who received RTX. Stabilization or improvement was observed in more than half of the patients in all studies. Evaluation based on pulmonary function tests (PFTs) noted disease progression in fewer than 20% of 7 out of 11 studies. Meta-analysis results revealed that, based on PFTs, the proportion of patients showing functional decline was 14.5% (95%CI, 7.6–25.8%) (95%PI, 2–69%); and according to the pulmonary high-resolution computed tomography (HRCT) evaluation, the proportion of worsening was 19.5% (95%CI, 8.1–40%) (95%PI, 1–84%). An overall acceptable safety profile was noted, with respiratory mortality ranging from 4% to 14%. Our review suggests that RTX appears to be an effective therapy in patients with RA-ILD, with a satisfactory safety profile. https://www.crd.york.ac.uk/prospero identifier is CRD420251049957.
DOI: 10.6084/m9.figshare.30219914
title: Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

description: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a systematic review with meta-analysis of studies involving patients with RA-ILD who were treated with RTX. Two investigators independently conducted the research. Twenty studies met the criteria for data extraction for the systematic review with a good quality assessment according to an 18-criteria checklist using a modified Delphi method. The total number of patients was 14,523, including 1,619 who received RTX. Stabilization or improvement was observed in more than half of the patients in all studies. Evaluation based on pulmonary function tests (PFTs) noted disease progression in fewer than 20% of 7 out of 11 studies. Meta-analysis results revealed that, based on PFTs, the proportion of patients showing functional decline was 14.5% (95%CI, 7.6–25.8%) (95%PI, 2–69%); and according to the pulmonary high-resolution computed tomography (HRCT) evaluation, the proportion of worsening was 19.5% (95%CI, 8.1–40%) (95%PI, 1–84%). An overall acceptable safety profile was noted, with respiratory mortality ranging from 4% to 14%. Our review suggests that RTX appears to be an effective therapy in patients with RA-ILD, with a satisfactory safety profile. https://www.crd.york.ac.uk/prospero identifier is CRD420251049957.
DOI: 10.6084/m9.figshare.29950411
title: Preparation of cationic liposomes loaded with Sirtuin 6 plasmid for the treatment of arthritis in rats

description: Arthritis, ormalizedn by chronic joint inflammation, is increasingly prevalent due to global ageing, placing significant pressure on healthcare systems. Recent studies have identified Sirtuin 6 (<i>Sirt6</i>) as a promising therapeutic target for alleviating arthritis symptoms. This study investigates the therapeutic potential of <i>Sirt6</i>-loaded cationic liposomes in a collagen-induced arthritis (CIA) rat model. <i>Sirt6</i>-loaded cationic liposomes were prepared and ormalizedn using transmission electron microscopy, particle size distribution, polydispersity index (PDI), zeta potential, encapsulation efficiency, <i>in vitro</i> release, and stability studies. The optimal <i>Sirt6</i> plasmid-to-liposome ratio was established at 1:1000. Characterisation confirmed a spherical morphology, with a particle size of 177.65 ± 2.09 nm, a PDI of 0.216 ± 0.013, and zeta potential of 21.78 ± 1.76 Mv. The liposomes exhibited superior release profiles and storage stability, thus maintaining their integrity for up to 30 days and achieving 90.77 ± 3.35% release efficiency within 24 h. <i>In vitro</i>, the endocytosis of <i>Sirt6</i>-loaded liposomes significantly increased <i>Sirt6</i> protein expression in chondrocytes (<i>p</i> &lt; 0.01). <i>In vivo</i>, treatment reduced inflammation in liver and spleen tissues and lowered pro-inflammatory cytokines associated with CIA (<i>p</i> &lt; 0.01). These findings support <i>Sirt6</i>-loaded liposomes as a potential novel therapeutic strategy for treatment of arthritis.
DOI: 10.6084/m9.figshare.29950411.v1
title: Preparation of Cationic Liposomes Loaded with Sirtuin 6 Plasmid for the Treatment of Arthritis in Rats

description: Arthritis, characterized by chronic joint inflammation, is increasingly prevalent due to global aging, placing significant pressure on healthcare systems. Recent studies have identified Sirtuin 6 (<i>Sirt6</i>) as a promising therapeutic target for alleviating arthritis symptoms. This study investigates the therapeutic potential of <i>Sirt6</i>-loaded cationic liposomes in a collagen-induced arthritis (CIA) rat model. <i>Sirt6</i>-loaded cationic liposomes were prepared and characterized using transmission electron microscopy, particle size distribution, polydispersity index (PDI), zeta potential, encapsulation efficiency, in vitro release, and stability studies. The optimal <i>Sirt6</i> plasmid-to-liposome ratio was established at 1:1000. Characterization confirmed a spherical morphology, with a particle size of 177.65 ± 2.09 nm, a PDI of 0.216 ± 0.013, and zeta potential of 21.78 ± 1.76 mV. The liposomes exhibited superior release profiles and storage stability, thus maintaining their integrity for up to 30 days and achieving 90.77 ± 3.35% release efficiency within 24 hours. <i>In vitro</i>, the endocytosis of <i>Sirt6</i>-loaded liposomes significantly increased <i>Sirt6</i> protein expression in chondrocytes (<i>P</i> &lt; 0.01). <i>In vivo</i>, treatment reduced inflammation in liver and spleen tissues and lowered pro-inflammatory cytokines associated with CIA (<i>P</i> &lt; 0.01). These findings support <i>Sirt6</i>-loaded liposomes as a potential novel therapeutic strategy for treatment of arthritis.
DOI: 10.6084/m9.figshare.29950411.v2
title: Preparation of cationic liposomes loaded with Sirtuin 6 plasmid for the treatment of arthritis in rats

description: Arthritis, ormalizedn by chronic joint inflammation, is increasingly prevalent due to global ageing, placing significant pressure on healthcare systems. Recent studies have identified Sirtuin 6 (<i>Sirt6</i>) as a promising therapeutic target for alleviating arthritis symptoms. This study investigates the therapeutic potential of <i>Sirt6</i>-loaded cationic liposomes in a collagen-induced arthritis (CIA) rat model. <i>Sirt6</i>-loaded cationic liposomes were prepared and ormalizedn using transmission electron microscopy, particle size distribution, polydispersity index (PDI), zeta potential, encapsulation efficiency, <i>in vitro</i> release, and stability studies. The optimal <i>Sirt6</i> plasmid-to-liposome ratio was established at 1:1000. Characterisation confirmed a spherical morphology, with a particle size of 177.65 ± 2.09 nm, a PDI of 0.216 ± 0.013, and zeta potential of 21.78 ± 1.76 Mv. The liposomes exhibited superior release profiles and storage stability, thus maintaining their integrity for up to 30 days and achieving 90.77 ± 3.35% release efficiency within 24 h. <i>In vitro</i>, the endocytosis of <i>Sirt6</i>-loaded liposomes significantly increased <i>Sirt6</i> protein expression in chondrocytes (<i>p</i> &lt; 0.01). <i>In vivo</i>, treatment reduced inflammation in liver and spleen tissues and lowered pro-inflammatory cytokines associated with CIA (<i>p</i> &lt; 0.01). These findings support <i>Sirt6</i>-loaded liposomes as a potential novel therapeutic strategy for treatment of arthritis.
DOI: 10.6084/m9.figshare.29619408.v1
title: Protein Biomarker Modulation and Wound Healing Efficacy of Mentha piperita-Based Green-Synthesized Silver Nanoparticles in Alloxan-Induced Diabetic Rats

description: The stability of <i>Mentha piperita</i>-silver nanoparticles (MPAgNPs), their hydrodynamic size, and expression of potential biomarkers in diabetic rat wounds, pre- and post-healing, were studied <i>in vivo</i>. State-of-the-art analytical techniques were used to characterize them. Scanning and transmission electron microscopy revealed spherical core metallic sizes of 50 nm. Dynamic light scattering determines the MPAgNPs hydrodynamic size of 127 nm. The zeta potential value of -15.4 mV confirmed the NP's stability. Medioresinol, Rosmarinic Acid, Caffeic acid, Salvianolic acid, and methyl syringate were the bioactive compounds identified in M. piperita by Liquid chromatography-tandem mass spectrometry. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis shows anti-inflammatory, anti-apoptotic, antioxidant, and defense proteins differential expression. Antioxidant assays show increased levels of superoxide dismutase (0.06 U/mL) and glutathione peroxidase (32.5 U/mL), with decreased malondialdehyde. Quantitative Reverse transcriptase polymerase chain reaction confirmed enhanced expression of transforming growth factor (TGF-β1), Thrombin, and Glutathione S-transferase P. At the same time, Tumor necrosis factor alpha (TNF-α), and Interleukin (IL-6) show reduced expression 16-D after MPAgNPs treatment. It served as a novel therapy for treating cutaneous wounds by modulating mechanisms involved in the inflammatory, proliferative, and tissue-remodeling phases.
DOI: 10.6084/m9.figshare.30806838
title: Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

description: The combination of MEK and BRAF inhibitors is effective in melanomas and other tumors with BRAF V600E mutations. MEK inhibitors enhance efficacy and delay the development of resistance to BRAF inhibitors. Recently, MEK inhibitors have demonstrated activity in plexiform neurofibromas in patients with type 1 neurofibromatosis and in histiocytic neoplasms. In the preclinical setting, MEK inhibitors are effective in tumors with RAS or receptor tyrosine kinase mutations. However, after the inhibition of MEK, regulatory feedback determines the rebound activation of ERK, thereby limiting the effect of the MEK blockade. In early clinical trials, MEK inhibitor monotherapy has shown limited efficacy in RAS-mutated tumors, whereas trials combining MEK and RAS inhibitors are still ongoing. Clinical trials have been selected from clinicaltrials.gov searching for ‘MEK inhibitors,’ and their results have been searched in PubMed and meeting abstracts. Preclinical studies have been searched in PubMed using the names of the MEK inhibitors. This is a descriptive review. While MEK inhibitors in combination with BRAF inhibitors obtained one of the first tumor-agnostic FDA approvals for BRAF V600E/K mutated tumors, additional indications for MEK inhibitors alone have been received in very selected diseases for which molecular characterization is crucial.
DOI: 10.6084/m9.figshare.30806838.v1
title: Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

description: The combination of MEK and BRAF inhibitors is effective in melanomas and other tumors with BRAF V600E mutations. MEK inhibitors enhance efficacy and delay the development of resistance to BRAF inhibitors. Recently, MEK inhibitors have demonstrated activity in plexiform neurofibromas in patients with type 1 neurofibromatosis and in histiocytic neoplasms. In the preclinical setting, MEK inhibitors are effective in tumors with RAS or receptor tyrosine kinase mutations. However, after the inhibition of MEK, regulatory feedback determines the rebound activation of ERK, thereby limiting the effect of the MEK blockade. In early clinical trials, MEK inhibitor monotherapy has shown limited efficacy in RAS-mutated tumors, whereas trials combining MEK and RAS inhibitors are still ongoing. Clinical trials have been selected from clinicaltrials.gov searching for ‘MEK inhibitors,’ and their results have been searched in PubMed and meeting abstracts. Preclinical studies have been searched in PubMed using the names of the MEK inhibitors. This is a descriptive review. While MEK inhibitors in combination with BRAF inhibitors obtained one of the first tumor-agnostic FDA approvals for BRAF V600E/K mutated tumors, additional indications for MEK inhibitors alone have been received in very selected diseases for which molecular characterization is crucial.
DOI: 10.6084/m9.figshare.30636800
title: Blood and adipose tissue DNA methylation in adults born preterm with a very low birth weight – a sibling comparison study

description: Preterm birth and very low birth weight (VLBW; &lt;1500 g) increase risks for poor health outcomes, potentially mediated by epigenetic modifications such as DNA methylation (DNAm). We hypothesized that DNAm differs between VLBW adults and their siblings in blood and adipose tissue. We studied 75 adults born preterm with VLBW and 73 same-sex sibling controls from the Adults Born Preterm Sibling Study. DNAm at cytosine–guanine dinucleotide (CpG) sites in blood and adipose tissue was assessed using Illumina EPIC 850K at a mean age of 29 years. Biological pathways were investigated with QIAGEN ingenuity pathway analysis (IPA). No differences were observed in blood DNAm. In adipose tissue, 458 CpG sites were differentially methylated (FDR <i>p</i> &lt; 0.05) between VLBW and siblings. Top sites were annotated to genes related to lipid metabolism (cg00264176 (<i>FADS2)</i>, 0.077 (0.007), FDR <i>p</i> = 3.24 × 10<sup>−14</sup>) and neural development (cg08277679 (<i>KIF26A)</i>, 0.053 (0.005), FDR <i>p</i> = 8.22 × 10<sup>−12</sup>). IPA identified enrichment for 81 pathways (FDR <i>p</i> &lt; 0.05). Our results suggest tissue-specific DNAm differences in VLBW adults compared to their siblings. The changes cluster in pathways related to lipid metabolism, neurodevelopment, and cardiometabolic regulation, suggesting lasting tissue-specific epigenetic modifications in VLBW adults. This study looked at how being born very early and very small (birth weight less than 1500 g) might affect long-term health through changes in genetic material DNA. We focused on a process called DNA methylation (DNAm). DNAm affects how actively genes work. We compared 75 adults born very small and premature to 73 of their siblings. We analyzed DNAm in blood and fat tissue when participants were 29 years old. No differences were found in blood samples. However, in fat tissue, we found 458 spots on the genetic material DNA that were activated differently in VLBW adults compared to their siblings. These changes were linked to genes involved in fat processing, heart health, and brain development. The findings suggest that being born early and very small cause lasting changes in how genes work in fat tissue. This could explain why adults who are born very small have higher risks for heart and metabolic diseases. These insights may help guide future treatments to improve health outcomes for people born premature or small.